Kapp, J. N., Verdurmen, W. P. R., Schaefer, J. V., Kopra, K., Nagy-Davidescu, G., Richard, E., Nokin, M.-J., Ernst, P., Tamaskovic, R., Schwill, M., Degen, R., Scholl, C., Santamaria, D., & Plückthun, A. (2025). A nucleotide-independent, pan-RAS-targeted DARPin elicits anti-tumor activity in a multimodal manner. Molecular Oncology. doi:10.1002/1878-0261.70061 |
Pilard, C., RONCARATI, P., Ancion, M., Luyckx, M., Renard, M., Reynders, C., Lerho, T., Poulain, F., Bruyère, D., LEBEAU, A., Hendrick, E., Crake, R., Peiffer, R., Nokin, M.-J., Peulen, O., Delvenne, P., Hubert, P.* , & Herfs, M.*. (13 March 2025). RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells. Journal for ImmunoTherapy of Cancer, 13 (3), 010753. doi:10.1136/jitc-2024-010753 * These authors have contributed equally to this work. |
Kramer-Drauberg, M., Petrini, E., Mira, A., Patrucco, E., Scardaci, R., Savinelli, I., Wang, H., Qiao, K., Carrà, G., Nokin, M.-J., Zhou, Z., Westover, K. D., Santamaria, D., Porporato, P. E., & Ambrogio, C. (February 2025). Oncogenic mutant KRAS inhibition through oxidation at cysteine 118. Molecular Oncology, 19 (2), 311 - 328. doi:10.1002/1878-0261.13798 |
Nokin, M.-J.* , Mira, A.* , Patrucco, E., Ricciuti, B., Cousin, S., Soubeyran, I., San José, S., Peirone, S., Caizzi, L., Michelina, S. V., Boudon, A., Wang, X., Alvarez-Villanueva, D., Martinez-Iniesta, M., Vidal, A., Rodrigues, T., Garcia-Macias, C., Awad, M. M., Nadal, E., ... Ambrogio, C. (2024). RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. Nature Communications. doi:10.1038/s41467-024-51828-2 * These authors have contributed equally to this work. |
Nokin, M.-J., Darbo, E., Richard, E., San José, S., de Hita, S., Prouzet-Mauleon, Turcs, B., Gerardelli, L., Crake, R., Velasco, V., KOOPMANSCH, B., Lambert, F., Xue, J. Y., Sang, B., Horne, J., Ziemons, E., Villanueva, A., Blomme, A., Herfs, M., ... Santamaria, D. (2024). In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma. Cell Reports Medicine. doi:10.1016/j.xcrm.2024.101663 |
Crake, R., Kiweler, N., Thiry, M., Peulen, O., Blomme, A., Meiser, J., Ambrogio, C., Santamaria, D., Cataldo, D., & Nokin, M.-J. (June 2023). Targeting metabolic adaptations in drug tolerant BRAFV600E mutant NSCLC [Poster presentation]. EACR 2023, Torino, Italy. |
Dube, G., Tiamiou, A., Bizet, M., Boumahd, Y., Gasmi, I., Crake, R., Bellier, J., Nokin, M.-J., Calonne, E., Deplus, R., Wissocq, T., Peulen, O., Castronovo, V., Fuks, F., & Bellahcene, A. (31 March 2023). Methylglyoxal: a novel upstream regulator of DNA methylation. Journal of Experimental and Clinical Cancer Research, 42 (1), 78. doi:10.1186/s13046-023-02637-w |
Bendavid, G., Hubeau, C., Perin, F., Gillard, A., Nokin, M.-J., Carnet, O., Gerard, C., Noël, A., Lefèbvre, P., Rocks, N., & Cataldo, D. (05 January 2023). Role for the metalloproteinase ADAM28 in the control of airway inflammation, remodelling and responsiveness in asthma. Frontiers in Immunology, 13. doi:10.3389/fimmu.2022.1067779 |
Kaminski, H., Marseres, G., Yared, N., Nokin, M.-J., Pitard, V., Zouine, A., Garrigue, I., Loizon, S., Capone, M., Gauthereau, X., Mamani-Matsuda, M., Coueron, Duran, R. V., Pinson, B., Pellegrin, I., Thiébaut, R., Couzi, L., Merville, P., & Dechanet-Merville, J. (January 2022). mTOR Inhibitors Prevent CMV Infection through the Restoration of Functional αβ and γδ T cells in Kidney Transplantation. Journal of the American Society of Nephrology, 33 (1), 121-137. doi:10.1681/ASN.2020121753 |
Ricciuti, B., Son, J., Okoro, J. J., Mira, A., Patrucco, E., Eum, Y., Wang, X., Paranal, R., Wang, H., Lin, M., Haikala, H. M., Li, J., Xu, Y., Alessi, J. V., Chloeu, C., Redig, A. J., Kohler, J., Dholakia, K. H., Chen, Y., ... Ambrogio, C. (2022). Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer. Clinical Cancer Research. |
Nguyen, T. L.* , Nokin, M.-J.* , Teres, S., Tome, M., Bodineau, C., Galmar, O., Pasquet, J.-M., Roussea, B., van Liempd, S., Falcon-Perez, J. M., Richard, E., Muzotte, E., Rezvani, H.-R., Priault, M., Bouchecareilh, M., Redonnet-Vernhet, I., Calvo, J., Uzan, B., Pflumio, F., ... Duran, R. V. (May 2021). Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1-driven acute lymphoblastic leukemia. Molecular Oncology, 15 (5), 1412-1431. doi:10.1002/1878-0261.12877 * These authors have contributed equally to this work. |
Nokin, M.-J., Ambrogio, C., Nadal, E., & Santamaria, D. (May 2021). Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. Trends in Cancer, 7 (5), 410-429. doi:10.1016/j.trecan.2020.11.005 |
Hubert, P., RONCARATI, P., Demoulin, S., Pilard, C., Ancion, M., Reynders, C., Lerho, T., Bruyère, D., Lebeau, A., Radermecker, C., Meunier, M., Nokin, M.-J., Hendrick, E., Peulen, O., Delvenne, P., & Herfs, M. (2021). Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Journal for ImmunoTherapy of Cancer, 9 ((3)), 001966. doi:10.1136/jitc-2020-001966 |
Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., KOOPMANSCH, B., MacKay, G. M., Chiavarina, B., Costanza, B., Rademaker, G., Durieux, F., Agirman, F., Maloujahmoum, N., Cusumano, P. G., LOVINFOSSE, P., Leung, H. Y., LAMBERT, F., Bours, V., ... Bellahcene, A. (04 February 2020). Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab. Cell Reports, 30 (5), 1400-1416.e6. doi:10.1016/j.celrep.2020.01.012 |
Nokin, M.-J., Bellier, J., Durieux, F., Peulen, O., Rademaker, G., Gabriel, M., Monseur, C., CHARLOTEAUX, B., Verbeke, L., van Laere, S., RONCARATI, P., Herfs, M., Lambert, C., Scheijen, J., Schalkwijk, C., Colige, A., Caers, J., Delvenne, P., Turtoi, A., ... Bellahcene, A. (2019). Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer. Breast Cancer Research, 21(1, 11. doi:10.1186/s13058-018-1095-7 |
Rademaker, G., Hennequière, V., Nokin, M.-J., LOVINFOSSE, P., Durieux, F., GOFFLOT, S., Bellier, J., Costanza, B., Herfs, M., Peiffer, R., Bettendorff, L., Deroanne, C., Thiry, M., Delvenne, P., Hustinx, R., Bellahcene, A., Castronovo, V., & Peulen, O. (April 2018). Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness. Oncogene, 37 ((32)), 4398-4412. doi:10.1038/s41388-018-0287-z |
Chiavarina, B., Nokin, M.-J., Bellier, J., Durieux, F., BLETARD, N., Sherer, F., LOVINFOSSE, P., Peulen, O., Verset, L., Dehon, R., Demetter, P., Turtoi, A., Uchida, K., Goldman, S., Hustinx, R., Delvenne, P., Castronovo, V., & Bellahcene, A. (2017). Methylglyoxal-Mediated Stress Correlates with High Metabolic Activity and Promotes Tumor Growth in Colorectal Cancer. International Journal of Molecular Sciences, 18 (1). doi:10.3390/ijms18010213 |
Nokin, M.-J., Durieux, F., Bellier, J., Peulen, O., Uchida, K., Spiegel, D. A., Cochrane, J. R., Hutton, C. A., Castronovo, V., & Bellahcene, A. (2017). Hormetic potential of methylglyoxal, a side-product of glycolysis, in switching tumours from growth to death. Scientific Reports, 7 (1), 11722. doi:10.1038/s41598-017-12119-7 |
Nokin, M.-J., Durieux, F., Peixoto, P., Chiavarina, B., Peulen, O., Blomme, A., Turtoi, A., Costanza, B., Smargiasso, N., Baiwir, D., Scheijen, J., Schalkwijk, C., Leenders, J., De Tullio, P., BIANCHI, E., Thiry, M., Uchida, K., Spiegel, D., Cochrane, J., ... Bellahcene, A. (2016). Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP- mediated tumor growth and metastasis. eLife. doi:10.7554/eLife.19375 |
Nokin, M.-J. (2016). Role of carbonyl stress in breast cancer progression and metastases development [Doctoral thesis, Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/314907 |
Henry, A., Nokin, M.-J., Leroi, N., Lallemand, F., Lambert, J., Goffart, N., RONCARATI, P., BIANCHI, E., Peixoto, P., Blomme, A., Turtoi, A., Peulen, O., Habraken, Y., Scholtes, F., Martinive, P., Delvenne, P., Rogister, B., Castronovo, V., & Bellahcene, A. (2016). New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity. Oncotarget. doi:10.18632/oncotarget.11483 |
Nokin, M.-J., Durieux, F., Peixoto, P., Chiavarina, B., Smargiasso, N., Baiwir, D., De Pauw, E., De Tullio, P., Thiry, M., Peulen, O., Turtoi, A., Castronovo, V., & Bellahcene, A. (27 January 2015). Accumulation of methylglyoxal, a glycolysis by-product modulates YAP1 transcription co-factor localization and activity in human breast cancer cells through HSP90 modification [Poster presentation]. GIGA-DAY: Current advances in medical genetics and genomics, Liège, Belgium. |
Chiavarina, B.* , Nokin, M.-J.* , Durieux, F., BIANCHI, E., Turtoi, A., Peulen, O., Peixoto, P., Irigaray, P., Uchida, K., Belpomme, D., Delvenne, P., Castronovo, V., & Bellahcene, A. (2014). Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes. Oncotarget. doi:10.18632/oncotarget.2121 * These authors have contributed equally to this work. |
Lamour, V., Nokin, M.-J., Henry, A., Castronovo, V., & Bellahcene, A. (2013). Les proteines SIBLING - Outils moleculaires de la progression tumorale et de l'angiogenese. MS. Medecine Sciences, 29 (11), 1018-25. doi:10.1051/medsci/20132911019 |